<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neratinib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neratinib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Neratinib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="114087" href="/d/html/114087.html" rel="external">see "Neratinib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F50442104"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Nerlynx</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F53998154"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Nerlynx</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F50424129"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anti-HER2;</li>
<li>
                        Antineoplastic Agent, Epidermal Growth Factor Receptor (EGFR) Inhibitor;</li>
<li>
                        Antineoplastic Agent, Tyrosine Kinase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F50442324"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> If not utilizing neratinib dose escalation, administer antidiarrheal prophylaxis during the first 56 days of therapy; initiate with the first neratinib dose (see "Premedications").</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d2db1859-04c1-4b41-87f5-7f089a21b6e8">Breast cancer, HER2-positive, advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, HER2-positive, advanced or metastatic:</b> 240 mg once daily on days 1 to 21 of a 21-day cycle (in combination with capecitabine [on days 1 to 14 only]) until disease progression or unacceptable toxicity (Saura 2020).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="022f7f12-da65-4937-8cd6-61f59c88cfbd">Breast cancer, HER2-positive, early stage, extended adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, HER</b>
<b>2-positive, early stage, extended adjuvant therapy:</b>
<b>Oral:</b> 240 mg once daily (as a single agent) until disease recurrence or for up to 1 year (Chan 2016).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dose</b>
<b> escalation strategy: </b>To improve neratinib tolerability and decrease the rate, severity, and duration of neratinib-induced diarrhea, a dose escalation strategy may be utilized for patients with early stage and metastatic breast cancer (Barcenas 2020). If diarrhea occurs, manage with antidiarrheal medications, fluid, and electrolytes, as clinically indicated; may also require neratinib treatment interruption and dosage reduction.</p>
<p style="text-indent:-2em;margin-left:4em;">Week 1 (days 1 to 7): Neratinib 120 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Week 2 (days 8 to 14): Neratinib 160 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Week 3 (day 15 and thereafter): Neratinib 240 mg once daily.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Missed dose:</b> If a dose is missed, resume neratinib with the next scheduled daily dose; do not replace the missed dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Premedication (manufacturer's labeling):</b> If not utilizing neratinib dose escalation, administer antidiarrheal prophylaxis during the first 56 days of neratinib therapy (beginning with the first neratinib dose). After day 56, titrate loperamide to achieve 1 to 2 bowel movements/day. Additional antidiarrheal medication, fluids, and electrolytes may be required for loperamide-refractory diarrhea.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neratinib weeks 1 to 2 (days 1 to 14):</i> Loperamide 4 mg orally 3 times daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neratinib weeks 3 to 8 (days 15 to 56):</i> Loperamide 4 mg orally twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neratinib week 9 to neratinib discontinuation:</i> Loperamide 4 mg as needed (maximum: 16 mg/day; titrate loperamide dose to achieve 1 to 2 bowel movements per day).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>The addition of budesonide or colestipol to loperamide prophylaxis has also been described to decrease the rate, severity, and duration of neratinib-induced diarrhea (Barcenas 2020):</p>
<p style="text-indent:-2em;margin-left:6em;">Budesonide 9 mg orally once daily in the morning for the first 28 days, in addition to loperamide prophylaxis as described above.</p>
<p style="text-indent:-2em;margin-left:6em;">Colestipol 2 g orally twice daily for the first 28 days, in addition to loperamide prophylaxis as described above.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990067"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, renal function does not have a clinically significant effect on neratinib pharmacokinetics.</p></div>
<div class="block doha drugH1Div" id="F50987352"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Preexisting hepatic impairment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate (Child-Pugh class A or B) impairment: No initial neratinib dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe (Child-Pugh class C) impairment: Reduce initial neratinib dose to 80 mg once daily.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">ALT or AST &gt;5 to 20 times ULN (grade 3) or bilirubin &gt;3 to 10 times ULN (grade 3): Interrupt neratinib until recovery to ≤ grade 1 (evaluate for alternative hepatotoxic causes); resume neratinib at the next lower dose level (see tables in "Dosage Adjustment for Toxicity") if recovery to ≤ grade 1 occurs within 3 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">Recurrent grade 3 ALT, AST, or bilirubin elevation despite one dose reduction: Permanently discontinue neratinib.</p>
<p style="text-indent:-2em;margin-left:4em;">ALT or AST &gt;20 times ULN (grade 4) or bilirubin &gt;10 times ULN (grade 4): Permanently discontinue neratinib and evaluate for alternative hepatotoxic causes.</p></div>
<div class="block dot drugH1Div" id="F50442330"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Discontinue neratinib if adverse reaction does not recover to ≤ grade 1 or baseline, or for toxicities that result in a treatment delay of &gt;3 weeks.</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption>
<b>Neratinib Monotherapy Dose Reduction Levels for Adverse Reactions</b></caption>
<colgroup><col/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Dose level</p></th>
<th align="center">
<p style="text-indent:0em;">Neratinib dose</p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;">Recommended starting dose</p></td>
<td align="center">
<p style="text-indent:0em;">240 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">First dose reduction</p></td>
<td align="center">
<p style="text-indent:0em;">200 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Second dose reduction</p></td>
<td align="center">
<p style="text-indent:0em;">160 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Third dose reduction</p></td>
<td align="center">
<p style="text-indent:0em;">120 mg once daily</p></td></tr>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;">Discontinue if unable to tolerate neratinib 120 mg once daily.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption>
<b>Neratinib (in Combination with Capecitabine<sup>a</sup>) Dose Reduction Levels for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Dose level</p></th>
<th align="center">
<p style="text-indent:0em;">Neratinib dose</p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="2" valign="middle">
<p style="text-indent:0em;">
<sup>a</sup> Capecitabine may also require dose adjustment due to toxicity; refer to Capecitabine monograph for further information.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">Recommended neratinib starting dose</p></td>
<td align="center">
<p style="text-indent:0em;">240 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">First neratinib dose reduction</p></td>
<td align="center">
<p style="text-indent:0em;">160 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Second neratinib dose reduction</p></td>
<td align="center">
<p style="text-indent:0em;">120 mg once daily</p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;">Discontinue if unable to tolerate neratinib 120 mg once daily.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption>
<b>Neratinib Monotherapy Dose Modifications</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Adverse reaction</p></th>
<th align="center">
<p style="text-indent:0em;">Severity</p></th>
<th align="center">
<p style="text-indent:0em;">Management</p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;">
<sup>a</sup> Complicated features include dehydration, fever, hypotension, renal failure, or grade 3 or 4 neutropenia.</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;">
<sup>b</sup> Despite being treated with optimal medical therapy.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;">Diarrhea</p></td>
<td align="center">
<p style="text-indent:0em;">• Grade 1 diarrhea (increase of &lt;4 stools/day over baseline)</p>
<p style="text-indent:0em;">• Grade 2 diarrhea (increase of 4 to 6 stools/day over baseline) lasting ≤5 days</p>
<p style="text-indent:0em;">• Grade 3 diarrhea (increase of ≥7 stools/day over baseline; incontinence; hospitalization indicated; limiting self-care activities of daily living) lasting ≤2 days</p></td>
<td align="center">
<p style="text-indent:0em;">• Adjust antidiarrheal treatment.</p>
<p style="text-indent:0em;">• Diet modifications.</p>
<p style="text-indent:0em;">• Maintain fluid intake of ~2 L/day to avoid dehydration.</p>
<p style="text-indent:0em;">• Once diarrhea improves to ≤ grade 1 or baseline, initiate loperamide 4 mg with each subsequent neratinib dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">• Any grade diarrhea with complicated features<sup>a</sup></p>
<p style="text-indent:0em;">• Grade 2 diarrhea lasting &gt;5 days<sup>b</sup></p>
<p style="text-indent:0em;">• Grade 3 diarrhea lasting &gt;2 days<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;">• Interrupt neratinib treatment.</p>
<p style="text-indent:0em;">• Diet modifications.</p>
<p style="text-indent:0em;">• Maintain fluid intake of ~2 L/day to avoid dehydration.</p>
<p style="text-indent:0em;">• If diarrhea improves to ≤ grade 1 in 1 week or less, resume neratinib at the same dose.</p>
<p style="text-indent:0em;">• If diarrhea improves to ≤ grade 1 in longer than 1 week, resume neratinib at the next lower dose level.</p>
<p style="text-indent:0em;">• Once diarrhea improves to ≤ grade 1 or baseline, initiate loperamide 4 mg with each subsequent neratinib dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">• Grade 4 diarrhea (life-threatening consequences; urgent intervention indicated)</p></td>
<td align="center">
<p style="text-indent:0em;">• Permanently discontinue neratinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">• Recurrent ≥ grade 2 diarrhea occurring at 120 mg once daily neratinib dose</p></td>
<td align="center">
<p style="text-indent:0em;">• Permanently discontinue neratinib.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Other adverse reactions</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;">• Interrupt neratinib until recovery to ≤ grade 1 or baseline within 3 weeks of stopping treatment. Upon recovery, resume neratinib at the next lower dose level.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;">• Permanently discontinue neratinib.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption>
<b>Neratinib (in Combination with Capecitabine) Dose Modifications</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Adverse reaction</p></th>
<th align="center">
<p style="text-indent:0em;">Severity</p></th>
<th align="center">
<p style="text-indent:0em;">Management</p></th></tr></thead>
<tbody>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Diarrhea</p></td>
<td align="center">
<p style="text-indent:0em;">• Grade 1 diarrhea (increase of &lt;4 stools/day over baseline)</p>
<p style="text-indent:0em;">• Grade 2 diarrhea (increase of 4 to 6 stools/day over baseline) lasting ≤5 days</p>
<p style="text-indent:0em;">• Grade 3 diarrhea (increase of ≥7 stools/day over baseline; incontinence; hospitalization indicated; limiting self-care activities of daily living) lasting ≤2 days</p></td>
<td align="center">
<p style="text-indent:0em;">• Adjust antidiarrheal treatment.</p>
<p style="text-indent:0em;">• Continue neratinib and capecitabine at full doses.</p>
<p style="text-indent:0em;">• Diet modifications.</p>
<p style="text-indent:0em;">• Maintain fluid intake of ~2 L/day to avoid dehydration.</p>
<p style="text-indent:0em;">• Once diarrhea improves to ≤ grade 1 or baseline, initiate loperamide 4 mg with each subsequent neratinib dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">• Persisting and intolerable grade 2 diarrhea lasting &gt;5 days</p>
<p style="text-indent:0em;">• Grade 3 diarrhea lasting &gt;2 days</p>
<p style="text-indent:0em;">• Grade 4 diarrhea (life-threatening consequences; urgent intervention indicated)</p></td>
<td align="center">
<p style="text-indent:0em;">• Adjust antidiarrheal treatment.</p>
<p style="text-indent:0em;">• Hold neratinib and capecitabine until recovery to ≤ grade 1 or baseline.</p>
<p style="text-indent:0em;">• Diet modifications.</p>
<p style="text-indent:0em;">• Maintain fluid intake of ~2 L/day to avoid dehydration.</p>
<p style="text-indent:0em;">• If recovery occurs:</p>
<p style="text-indent:-2em;margin-left:2em;">1. ≤1 week after withholding treatment, resume same doses of neratinib and capecitabine.</p>
<p style="text-indent:-2em;margin-left:2em;">2. Within 1 to 3 weeks after withholding treatment, reduce neratinib dose to 160 mg, and maintain the same dose of capecitabine.</p>
<p style="text-indent:0em;">• If event occurs a second time and the neratinib dose has not already been decreased, reduce neratinib dose to 160 mg (maintain the same dose of capecitabine). If neratinib dose has already been reduced, then reduce the dose of capecitabine to ~550 mg/m<sup>2</sup> twice daily (maintain the same dose of neratinib).</p>
<p style="text-indent:0em;">• If subsequent events occur, reduce the dose of neratinib or capecitabine to the next lower dose level in an alternate fashion (ie, reduce capecitabine to ~375 mg/m<sup>2</sup> twice daily if neratinib was previously reduced, or reduce neratinib to 120 mg if capecitabine was previously reduced).</p>
<p style="text-indent:0em;">• Once diarrhea improves to ≤ grade 1 or baseline, initiate loperamide 4 mg with each subsequent neratinib dose.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Other adverse reactions</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;">• Interrupt neratinib until recovery to ≤ grade 1 or baseline within 3 weeks of stopping treatment. Upon recovery, resume neratinib at the next lower dose level.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue neratinib.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F50442327"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F50442367"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (36%; severe abdominal pain: &lt;1%), decreased appetite (12%), diarrhea (95%; severe diarrhea: 2%), nausea (43%; severe nausea: &lt;1%), stomatitis (14%; grade 3: &lt;1%), vomiting (26%; severe vomiting: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (27%; severe fatigue: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle spasm (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Nail disease (8%), skin fissure (2%), xeroderma (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (4%; severe dehydration: &lt;1%), weight loss (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distension (5%), dyspepsia (10%), xerostomia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (9% to 10%; severely increased serum alanine aminotransferase: &lt;1%), increased serum aspartate aminotransferase (5% to 7%; severely increased serum aspartate aminotransferase: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cellulitis, erysipelas</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal failure syndrome</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hepatic: Hepatotoxicity</p></div>
<div class="block coi drugH1Div" id="F50424124"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to neratinib or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F50442294"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicity: Severe diarrhea, which may result in dehydration, hypotension, and renal failure, has been observed commonly with neratinib (both as monotherapy and in combination with capecitabine) treatment. The majority of patients receiving neratinib in clinical trials experienced diarrhea; most developed diarrhea during the first month of treatment (antidiarrhea prophylaxis was not required in one trial, although was required during cycle one in another trial). The median time to onset of ≥ grade 3 diarrhea was 8 to 11 days (range: 1 day to 728 days); the median cumulative duration of toxicity was 3 to 5 days (range: 1 day to 139 days). When patients initiated neratinib therapy utilizing a dose escalation strategy, the median time to onset of ≥ grade 3 diarrhea was 45 days (range: 15 to 132 days); the median cumulative duration of toxicity was 2.5 days (range: 1 to 6 days).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatoxicity: Hepatotoxicity characterized by elevated liver enzymes has been reported with neratinib therapy. ALT and AST elevations have been observed; transaminase elevations and hepatotoxicity have led to treatment discontinuation in some patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Neratinib clearance is reduced and exposure is increased in patients with severe preexisting hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: The incidence of serious adverse reactions and treatment discontinuation was higher in patients ≥65 years of age (compared to patients &lt;65 years of age) in clinical trials. The most commonly reported serious adverse reactions in elderly patients included vomiting, diarrhea, acute kidney injury, renal failure, and dehydration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Guidelines from the American Society of Clinical Oncology (ASCO) for selection of optimal adjuvant chemotherapy and targeted therapy in early breast cancer supports the use of extended adjuvant neratinib therapy in patients with early-stage human epidermal growth receptor type 2-positive, hormone receptor-positive, and node-positive breast cancer, with patients beginning neratinib within 1 year of completion of trastuzumab therapy deriving the most benefit (ASCO [Denduluri 2018]).</p></div>
<div class="block foc drugH1Div" id="F50442105"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as maleate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nerlynx: 40 mg</p></div>
<div class="block geq drugH1Div" id="F50442103"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F50454592"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Nerlynx Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $147.65</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F53998155"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as maleate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nerlynx: 40 mg</p></div>
<div class="block accres drugH1Div" id="F50442289"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;">Neratinib is available through select specialty pharmacies. Refer to http://www.nerlynx.com for further information.</p></div>
<div class="block adm drugH1Div" id="F50442333"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer orally with food at approximately the same time each day. Swallow tablets whole; do not crush, chew, or split tablets. Antidiarrheal prophylaxis is recommended during the first 8 weeks (if not utilizing neratinib dose escalation). Maintain adequate hydration.</p></div>
<div class="block hazard drugH1Div" id="F50442297"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Neratinib may cause teratogenicity, reproductive toxicity, and has a structural or toxicity profile similar to existing hazardous agents.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block meg drugH1Div" id="F51672756"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2018%2F208051s002lbl.pdf%23page%3D19&amp;token=zTWA%2BhOn%2B4CoBhjnZljps4uG2z2IMl3EPSNn0RyX0WzPo%2BpAw4dsSjB%2BZHYPLbI4%2FFLL8WXyBSsIQeVoXEGLE80HIoy0GXWwkqccdY%2FiD8h4Tdv9nGQAXi8PxqsbiyNm&amp;TOPIC_ID=114008" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208051s002lbl.pdf#page=19</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F50424123"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Extended adjuvant treatment (as a single agent) of early-stage HER2-positive breast cancer in adults (following adjuvant trastuzumab-based therapy).</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of advanced or metastatic HER2-positive breast cancer (in combination with capecitabine) in adults who have received 2 or more prior anti-HER2 based regimens in the metastatic setting.</p></div>
<div class="block mst drugH1Div" id="F50442287"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Neratinib may be confused with afatinib, binimetinib, ceritinib, dasatinib, enasidenib, erlotinib, imatinib, lapatinib, lenvatinib, nilotinib, nintedanib, niraparib, ponatinib, regorafenib, SUNItinib, vandetanib.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F50472876"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> P-glycoprotein/ABCB1</p></div>
<div class="block dri drugH1Div" id="F50472873"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: If combined, administer the P-gp inhibitor simultaneously with, or after, the dose of afatinib. Monitor closely for signs and symptoms of afatinib toxicity and if the combination is not tolerated, reduce the afatinib dose by 10 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the serum concentration of Neratinib. Specifically, antacids may reduce neratinib absorption. Management: Separate the administration of neratinib and antacids by giving neratinib at least 3 hours after the antacid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Berotralstat.  Management: Decrease the berotralstat dose to 110 mg daily when combined with P-glycoprotein (P-gp) inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: This combination is often contraindicated, but combined use may be permitted with dose adjustment and monitoring. Recommendations vary based on brand, indication, use of CYP3A4 inhibitors, and hepatic/renal function. See interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Neratinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Neratinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Neratinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Neratinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Digoxin.  Management: Measure digoxin serum concentrations before initiating treatment with these P-glycoprotein (P-gp) inhibitors. Reduce digoxin concentrations by either reducing the digoxin dose by 15% to 30% or by modifying the dosing frequency.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Liposomal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Edoxaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide Phosphate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Histamine H2 Receptor Antagonists: May decrease the serum concentration of Neratinib. Specifically, histamine H2 receptor antagonists may reduce neratinib absorption. Management: Administer neratinib at least 2 hours before or 10 hours after administration of a histamine H2 receptor antagonist to minimize the impact of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of CYP3A4 (Moderate) and P-glycoprotein: May increase the serum concentration of Neratinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May decrease the serum concentration of Neratinib. Specifically, proton pump inhibitors may reduce neratinib absorption.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Larotrectinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin tablets with P-glycoprotein/ABCB1 inhibitors. If concomitant use is required, monitor for lefamulin adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Morphine (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Morphine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Nadolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naloxegol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pralsetinib.  Management: If this combo cannot be avoided, decrease pralsetinib dose from 400 mg daily to 300 mg daily; from 300 mg daily to 200 mg daily; and from 200 mg daily to 100 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ranolazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix.  Management: Avoid coadministration of relugolix with oral P-gp inhibitors whenever possible. If combined, take relugolix at least 6 hours prior to the P-gp inhibitor and monitor patients more frequently for adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix, Estradiol, and Norethindrone: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix, Estradiol, and Norethindrone.  Management: Avoid use of relugolix/estradiol/norethindrone with P-glycoprotein (P-gp) inhibitors. If concomitant use is unavoidable, relugolix/estradiol/norethindrone should be administered at least 6 hours before the P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAXIMin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rimegepant.  Management: Avoid administration of another dose of rimegepant within 48 hours if given concomitantly with a P-glycoprotein (P-gp) inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RisperiDONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RomiDEPsin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RomiDEPsin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Conventional).  Management: Avoid concurrent use of sirolimus with P-glycoprotein (P-gp) inhibitors when possible and alternative agents with lesser interaction potential with sirolimus should be considered. Monitor for increased sirolimus concentrations/toxicity if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Protein Bound). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talazoparib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Talazoparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tegaserod (Withdrawn from US Market): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tegaserod (Withdrawn from US Market). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teniposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Teniposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Disoproxil Fumarate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 50 mg and second dose (at least 2 hours later if needed) of 50 mg when used with a P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring concomitant treatment with P-glycoprotein (P-gp) inhibitors. Resume the previous venetoclax dose 2 to 3 days after discontinuation of a P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F50442296"><span class="drugH1">Food Interactions</span>
<p style="text-indent:-2em;margin-left:2em;">A high-fat meal (~55% fat, 31% carbohydrate, and 14% protein) increases neratinib C<sub>max</sub> and AUC<sub>inf</sub> by 70% and 120%, respectively. A standard breakfast (~50% carbohydrate, 35% fat, and 15% protein) increased neratinib C<sub>max</sub> by 20% and AUC<sub>inf</sub> by 10%. Management: Administer with food.</p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit juice may increase neratinib exposure. Management: Avoid grapefruit juice.</p></div>
<div class="block rep_considerations drugH1Div" id="F53589438"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients who can become pregnant should have a pregnancy test prior to treatment; effective contraception should be used during therapy and for at least 1 month after the last neratinib dose.</p>
<p style="text-indent:0em;margin-top:2em;">Patients with partners who can become pregnant should also use effective contraception during therapy and for 3 months after the last neratinib dose.</p></div>
<div class="block pri drugH1Div" id="F50442292"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, use of neratinib in pregnancy may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F50442293"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if neratinib is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, breastfeeding is not recommended during therapy or for at least 1 month after the last neratinib dose.</p></div>
<div class="block mop drugH1Div" id="F50442335"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor LFTs (ALT, AST, bilirubin, and alkaline phosphatase) prior to treatment initiation, monthly for the first 3 months, then every 3 months thereafter or as clinically indicated; fractionated bilirubin and prothrombin time if clinically necessary. Also assess LFTs in patients with ≥ grade 3 diarrhea requiring IV fluids or in those with signs/symptoms of hepatotoxicity (worsening fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia). Evaluate pregnancy status prior to therapy initiation (in patients who can become pregnant). Monitor closely for diarrhea (and subsequent complications); stool cultures may be needed to exclude infectious etiologies for diarrhea. Monitor for signs/symptoms of dehydration and hepatotoxicity. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Cardiovascular monitoring: </i>Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017]; ESC [Lyon 2022]).</p></div>
<div class="block pha drugH1Div" id="F50442299"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Neratinib is an irreversible tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and HER4 (Chan 2016). Neratinib reduces EGFR and HER2 autophosphorylation and downstream MAPK and AKT signaling pathways and demonstrates antitumor activity in EGFR and/or HER2 expressing cancer cell lines.</p></div>
<div class="block phk drugH1Div" id="F50442300"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>ss</sub>/F: 6,433 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;99% to serum albumin and alpha-1 acid glycoprotein.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic via CYP3A4 (major) and flavin-containing monooxygenase (minor) to active metabolites M3, M6, M7, and M11.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 7 to 17 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 2 to 8 hours (parent drug and active metabolites M3, M6, and M7).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (~97%); urine (~1%).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 216 L/hour (following a single dose); 281 L/hour (at steady state).</p></div>
<div class="block phksp drugH1Div" id="F51154893"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Hepatic function impairment: Neratinib C<sub>max</sub> and AUC were increased by 173% and 181%, respectively, in patients with severe (Child-Pugh class C) hepatic impairment compared to subjects with normal hepatic function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F52003481"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Nerlynx</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neratinib-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32464281">
<a name="32464281"></a>Barcenas CH, Hurvitz SA, Di Palma JA, et al. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial. <i>Ann Oncol</i> 2020;S0923-7534(20)39833-1. doi: 10.1016/j.annonc.2020.05.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neratinib-drug-information/abstract-text/32464281/pubmed" id="32464281" target="_blank">32464281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26874901">
<a name="26874901"></a>Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncol.</i> 2016;17(3):367-377.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neratinib-drug-information/abstract-text/26874901/pubmed" id="26874901" target="_blank">26874901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29787356">
<a name="29787356"></a>Denduluri N, Chavez-MacGregor M, Telli ML, et al. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. <i>J Clin Oncol</i>. 2018 May 22:JCO2018788604. doi: 10.1200/JCO.2018.78.8604.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neratinib-drug-information/abstract-text/29787356/pubmed" id="29787356" target="_blank">29787356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neratinib-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J</i>. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neratinib-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nerlynx.1">
<a name="Nerlynx.1"></a>Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology Inc; March 2022.</div>
</li>
<li>
<div class="reference">
                  Nerlynx (neratinib) [product monograph]. Montreal, Quebec, Canada: Knight Therapeutics Inc; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32678716">
<a name="32678716"></a>Saura C, Oliveira M, Feng Y, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥2 HER2-directed regimens: phase III NALA trial. <i>J Clin Oncol</i> 2020;JCO2000147. doi:10.1200/JCO.20.00147<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neratinib-drug-information/abstract-text/32678716/pubmed" id="32678716" target="_blank">32678716</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed July 20, 2017.</div>
</li></ol></div><div id="topicVersionRevision">Topic 114008 Version 137.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
